AJR Not a Member? Click to Join ARRS!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ng, Q. S.
Right arrow Articles by Padhani, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, Q. S.
Right arrow Articles by Padhani, A. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
DOI:10.2214/AJR.05.0889
AJR 2006; 187:1079-1084
© American Roentgen Ray Society


Original Research

Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage?

Quan Sing Ng1, Vicky Goh2, Ernst Klotz3, Heinz Fichte3, Michele I. Saunders1, Peter J. Hoskin1 and Anwar R. Padhani2

1 Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom.
2 Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Rd., Northwood, Middlesex, United Kingdom HA6 2RN.
3 Siemens Medical Solutions, Forchheim, Germany.

Received May 25, 2005; accepted after revision August 16, 2005.

 
Address correspondence to V. Goh (vicky.goh{at}paulstrickland-scannercentre.org.uk).


Abstract
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
OBJECTIVE. To date, quantitative assessment of tumor vascularity using perfusion CT has been limited to a single tumor level, with the potential for measurement error in heterogeneous tumors. We aimed to determine if greater z-axis tumor coverage improves the reproducibility of perfusion CT measurements in lung cancer.

SUBJECTS AND METHODS. Paired perfusion studies were performed on 10 patients who had histologically confirmed advanced non-small cell lung cancer. Using 16-MDCT, multiple sequential volumetric acquisitions encompassing the entire tumor were acquired after infusion of IV contrast material. Using Patlak analysis, median values of tumor permeability (mL/100 mL/min) and blood volume (mL/100 mL) were measured for 10-mm z-axis coverage, and for 40-mm z-axis coverage in each of the paired perfusion studies. Measurement reproducibility was evaluated using Bland-Altman statistics.

RESULTS. Mean difference (95% limits of agreement) for tumor permeability was 1.4 (-4.0 to 6.8) for 10-mm coverage and 0.8 (-3.6 to 5.2) for 40-mm coverage. Mean difference (95% limits of agreement) for blood volume was 1.9 (-5.1 to 8.9) for 10-mm coverage and 1.4 (-3.7 to 6.6) for 40-mm coverage. The coefficient of variation for permeability was 18.7% for 10-mm coverage, improving to 11.9% for 40-mm coverage. The coefficient of variation for blood volume was 41.7% for 10-mm coverage, improving to 32.6% for 40-mm coverage.

CONCLUSION. Our results show that an improvement in tumor perfusion measurement reproducibility may be achieved with greater z-axis coverage.

Keywords: lung • lung diseases • MDCT • neoplasms • oncologic imaging • perfusion CT


Introduction
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
Over the next few years, an increasing number of vascular-modulating drugs will be used in the treatment of patients with cancer, which in turn will increase demand for noninvasive methods of assessing tumor vascularity in vivo [1]. The reasons for this are twofold. First, these drugs may not alter tumor size as a consequence of their action; thus, conventional criteria for therapeutic response assessment, based on tumor size change, have been inappropriate [2-4]. Second, these drugs tend to have a wider therapeutic window than conventional drugs. Thus, in early-phase dose-finding trials, relying solely on toxicity-based criteria to define a dose has been suboptimal. Biologic changes, assessed by these noninvasive methods, can be used to show proof of the mechanism of drug activity, and a lower dose than defined using toxicity-based criteria may be selected for further study.

Both dynamic contrast-enhanced MRI and perfusion CT have been used in clinical trials of vascular-modulating drugs to provide such assessment [5-8], although CT has the advantage of being more clinically accessible. Perfusion CT has been validated against a variety of techniques including microspheres, xenon CT, and oxygen-15-labeled H2O PET [9-14] and has been correlated against histologic markers of angiogenesis [15-17]. Until now, CT assessment of tumor perfusion has been limited to a single tumor level with z-axis coverage up to 24 mm. This may be potentially confounding because tumor vasculature is spatially heterogeneous [18, 19]. Greater tumor coverage has the potential to compensate for this heterogeneity and hence to improve measurement variability. This study aimed to determine if measurement reproducibility in lung cancer improves with increasing z-axis tumor coverage by comparing tumor perfusion measurements obtained from 10-mm z-axis tumor coverage with those from 40-mm coverage.


Subjects and Methods
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
Subjects
This prospective study was performed as part of a phase IB clinical trial of the vascular targeting agent combretastatin A-4 phosphate in combination with radiation therapy. Ethical approval was obtained from the local institutional ethics committee and each patient gave written informed consent. Ten patients (eight men, two women; mean age, 66 years; age range, 52-79 years) with histologically proven, inoperable non-small cell lung cancer (seven stage III, three stage IV; size range, 5.1-11 cm; mean, 8.3 cm) were enrolled prospectively into the study.


Figure 1
View larger version (63K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1A 72-year-old man with lung tumor. Region of interest (ROI) is drawn freehand around lung tumor.

 


Figure 2
View larger version (63K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1B 72-year-old man with lung tumor. Color parametric map of vascular blood volume or permeability is automatically generated by perfusion software. Each pixel within ROI corresponds to single perfusion value, allowing for pixel-by-pixel analysis.

 


Figure 3
View larger version (24K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1C 72-year-old man with lung tumor. Color parametric maps of vascular blood volume or permeability for four contiguous 10-mm axial levels. By amalgamating data from all individual pixels from four levels, tumor perfusion values can be derived for 40-mm z-axis coverage.

 
Imaging
Patients were scanned using a 16-MDCT scanner (Sensation 16, Siemens Medical Solutions). No additional patient preparation was required over and above that for a routine thoracic CT examination. An 18-gauge cannula was placed in an antecubital fossa vein while the patient lay supine on the scanner table. An initial unenhanced breath-hold helical scan was obtained using the following parameters: 80 kV; 120 mAs; table feed, 30 mm; rotation time, 0.5 seconds; collimation, 2 mm; detector width, 1.5 mm; scanning field of view (SFOV), 500 mm; matrix, 512 x 512 mm. This scan provided baseline unenhanced images and was used to plan the subsequent perfusion study.

Using a dual-headed pump injector (Injekttron CT2, Medtron), 100 mL of iobitridol 300 mg I/mL (Xenetix 300, Guerbet) was administered with a decreasing bolus infusion rate (32 mL at 4 mL/s, 16 mL at 2 mL/s, and 60 mL at 1 mL/s) and followed by a saline flush (20 mL at 1 mL/s). The rationale for the contrast-infusion protocol was to optimize conditions for the mathematic analysis model, Patlak analysis, by maintaining a more constant intravascular concentration of contrast material, minimizing the concentration gradient between the intravascular and extravascular spaces, and improving the signal-to-noise ratio during the acquisition.

A single-level bolus tracking scan (CARE bolus, Siemens) at the level of the aortic arch was commenced at the same time as contrast administration using the following parameters: 80 kV; 20 mAs; scanning time, 0.5 seconds; collimation, 4.5 mm; detector width, 0.75 mm. The dynamic study was triggered when peak aortic enhancement was identified from the aortic time-density curve during the bolus tracking scans. The dynamic study consisted of a total of eight breath-hold helical acquisitions, encompassing the entire tumor using the following parameters: 80 kV; 120 mAs; table feed, 30 mm; rotation time, 0.5 seconds; collimation, 2 mm; detector width, 1.5 mm; SFOV, 500 mm; matrix, 512 x 512 mm. Total dynamic acquisition time varied from patient to patient but was approximately 90 seconds. The entire CT perfusion study was repeated within 24 hours without intervening treatment, using identical technical parameters to allow assessment of measurement reproducibility.

Data Postprocessing and Analysis
Data were transferred to a dedicated workstation (Leonardo, Siemens Medical Solutions). There were a total of 20 perfusion studies (10 patients, two studies each) for evaluation by a single experienced investigator. Each perfusion study consisted of nine helical scans (one baseline scan and eight contrast-enhanced dynamic scans) that required postprocessing before quantitative perfusion analysis. For each scan, the 2-mm collimated axial images were reformatted into 10-mm-thick axial images using 3D software (3D Analysis, Siemens) to permit analysis within a clinically acceptable time.

Reformatted scans were checked to ensure that the whole tumor was included and that each of the reformatted axial images corresponded to a similar position along the z-axis of the patient on all nine scans by comparing the position of the tumor to adjacent anatomic structures. Then each reformatted 10-mm axial image from the same position along the z-axis of the patient from each of the nine helical scans was saved as a separate series on the workstation for further analysis. Thus, for each patient multiple series were obtained for each of the two dynamic studies, encompassing the entire tumor; each series consisted of a single baseline unenhanced image and eight dynamic contrast-enhanced axial images at the same tumor level. The number of series per patient varied depending on tumor size.

For each patient, all series of reformatted dynamic images, encompassing the whole tumor, were loaded into the prototype perfusion software (Siemens) based on Patlak analysis [20]. The arterial input was determined from the bolus tracking scan images for each patient; using an electronic cursor and the mouse, a circular region of interest (ROI) was placed within the aorta. An arterial time-attenuation curve was generated automatically, and this information was saved using the software for subsequent analysis.

A single, central 10-mm tumor level was chosen, and an ROI was drawn freehand around the tumor by a single experienced observer using an electronic cursor and mouse, taking care to exclude surrounding air and atelectatic lung where possible. A tissue attenuation-time curve was generated automatically by the software along with parametric maps of permeability and blood volume (Figs. 1A and 1B). Each pixel location within the functional map corresponded to a single quantitative perfusion value resulting from the mathematic calculation of the data at that location. Data were analyzed on a pixel-by-pixel basis, and median values of tumor permeability and blood volume were derived for this tumor level, equivalent to a 10-mm z-axis coverage. These values were recorded for each patient.

This process was repeated for another three adjacent tumor levels (Fig. 1C). By amalgamating data from all individual pixels from these three levels and the initial tumor level, median values for permeability and blood volume were calculated, producing values for z-axis coverage of 40 mm. Again, these values were recorded for each patient. Analysis of the second perfusion study from each patient was then repeated by the same observer, ensuring similar tumor levels as the first study to allow assessment of measurement reproducibility. Thus, for all 10 patients, median values of tumor permeability and blood volume for 10-mm z-axis coverage and for 40-mm z-axis coverage for both perfusion studies were documented for subsequent statistical evaluation.

Statistical Analysis
Initial analysis was performed to confirm that the statistical assumptions required for repeatability analysis were upheld. Kendall's tau statistic was used to establish any relationship between measurement error and the magnitude of the measurement. If the difference between measurements appeared to increase when the mean parameter value increased, the data were transformed by natural logarithm.

Bland and Altman [21-25] statistics were applied to determine the reproducibility between the repeated perfusion studies. The mean difference, SD, and 95% limits of agreement were established. The within-patient coefficient of variation, repeatability coefficient for an individual patient, and variance ratio were also estimated.


Results
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
All 20 perfusion scans were technically adequate and analyzed successfully. Because tumor permeability had a significant dependence of its difference on its mean value (Kendall's tau, p < 0.02), values were transformed by natural logarithm. The mean, mean difference, SD, 95% limits of agreement, and repeatability statistics for permeability and blood volume for 10-mm and 40-mm z-axis coverage are summarized in Table 1. Corresponding Bland-Altman agreement plots are shown in Figures 2A, 2B, 3A, and 3B.


View this table:
[in this window]
[in a new window]

 
TABLE 1: Reproducibility Statistics for Tumor Permeability and Blood Volume Measurements

 

Figure 4
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2A Bland-Altman agreement plots of permeability (mL/100 mL/min). Plots show difference in permeability between two scans against mean of permeability values for 10-mm (A) and 40-mm (B) tumor coverage. Narrowing of 95% limits of agreement with 40-mm coverage indicates improvement in measurement reproducibility.

 

Figure 5
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2B Bland-Altman agreement plots of permeability (mL/100 mL/min). Plots show difference in permeability between two scans against mean of permeability values for 10-mm (A) and 40-mm (B) tumor coverage. Narrowing of 95% limits of agreement with 40-mm coverage indicates improvement in measurement reproducibility.

 

Figure 6
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3A Bland-Altman agreement plots of blood volume (mL/100 mL). Plots show difference in blood volume between two scans against mean of blood volume values for 10-mm (A) and 40-mm (B) tumor coverage. Narrowing of 95% limits of agreement with 40-mm coverage indicates improvement in measurement reproducibility.

 

Figure 7
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3B Bland-Altman agreement plots of blood volume (mL/100 mL). Plots show difference in blood volume between two scans against mean of blood volume values for 10-mm (A) and 40-mm (B) tumor coverage. Narrowing of 95% limits of agreement with 40-mm coverage indicates improvement in measurement reproducibility.

 

The mean difference (95% limits of agreement) for tumor permeability was 1.4 (-4.0 to 6.8) for 10-mm coverage and 0.79 (-3.6 to 5.2) for 40-mm coverage. Mean difference (95% limits of agreement) for blood volume was 1.89 (-5.1 to 8.9) for 10-mm coverage and 1.4 (-3.7 to 6.6) for 40-mm coverage. Coefficient of variation for permeability was 18.7% for 10-mm coverage and 11.9% for 40-mm coverage. The coefficient of variation for blood volume was 41.7% for 10-mm coverage and 32.6% for 40-mm coverage. These results show that by increasing z-axis coverage from 10 to 40 mm, an improvement in measurement reproducibility for both perfusion parameters can be achieved.


Discussion
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
Perfusion CT provides a quantitative and noninvasive method of studying tumor vascular function and has been used increasingly as a tool for monitoring responses to treatment by vascular-modulating drugs. To date, quantitative perfusion CT techniques have been limited to a single tumor level, although a number of contiguous axial images at the same tumor level can now be acquired with MDCT scanners, depending on the row configuration. For example, with a 16-MDCT scanner, four contiguous 6-mm axial images can be acquired, giving 24-mm z-axis coverage. However, it is well recognized that tumor vasculature exhibits both spatial and temporal heterogeneity; blood flow can vary in different locations within a single tumor and at different time points depending on the tumor microenvironment [18, 19]. Therefore, single-level measurements of tumor perfusion might not provide a true representation of vascular function and will be prone to measurement error, especially in larger tumors, as found in our study cohort.

Single-level techniques have also been problematic for quantitative assessment of perfusion in lung lesions, not least because of image misregistration from respiratory motion during scan acquisition. For example, Miles et al. [26] reported that six of 16 perfusion CT studies of pulmonary nodules could not be analyzed due to image misregistration or beam-hardening artifact from high-density contrast medium within the venous system. To compensate for the spatial variation in tumor perfusion, a solution is to further increase the tumor volume assessed by perfusion CT. By obtaining multiple helical acquisitions dynamically, assessment of a large tumor volume is possible, which may decrease measurement error, thus improving measurement reproducibility. This is particularly important when repeated measurements are made on the same patient, for example, when assessing therapeutic drug effects. Obtaining multiple helical acquisitions dynamically will also reduce problems with image misregistration.

Measurement reproducibility can be evaluated using several indexes. The 95% limits of agreement represents the boundaries within which the true measurement is expected to lie 95% of the time; the narrower the limits, the more precise the measurement being made. The coefficient of variation quantifies the measurement error with respect to the mean and provides an estimation of precision. Both the 95% limits of agreement and the coefficient of variation of our technique are acceptable for response assessment and are comparable to data from the cranial circulation in animals, in which coefficients of variation for cerebral perfusion ranging from 12% to 35% have been reported [27, 28], and data from animal tumor models, in which coefficients of variation for perfusion have ranged from 14% to 24% [9]. More important, an improvement was noted when the z-axis coverage increased from 10 to 40 mm. For example, the coefficient of variation for tumor permeability improved from 18.7% to 11.9%; similarly, limits of agreement narrowed from a range of -4.0 to 6.8 to a range of -3.6 to 5.2. Furthermore, our results compare favorably to single-level dynamic contrast-enhanced MRI reproducibility in human tumors [29], in which the coefficient of variation in log10Ktrans, a measurement of permeability, was 24%.

The repeatability coefficient indicates the 95% confidence limits that might occur spontaneously in an individual. An improvement from 0.5 to 0.3 was shown for tumor permeability when tumor coverage increased from 10 to 40 mm, indicating a decrease in measurement variability. This was also supported by the ratio of between-patient variance to within-patient variance, which increased from 12.4 to 14.2, indicating that perfusion measurements derived from a greater tumor volume may be more sensitive to variations in the parameter studied and less variable when repeated studies are performed on the same individual. This degree of measurement variability is well within the levels of expected therapeutic effect of current antiangiogenic and antivascular drugs undergoing clinical evaluation—for example, bevacizumab (Avastin, Genentech) [5] and combretastatin (OxiGene) (Ng QS et al., presented at the 2003 annual meeting of the European Society for Therapeutic Radiology and Oncology)— but the ability to improve on the reproducibility of this perfusion CT technique bodes well for future clinical utility.

Although we have established that reproducibility of perfusion CT measurements can be improved with increasing tumor coverage, one limitation of this analysis is that it merely provides an overall measure of measurement variability. It does not distinguish among the extrinsic factors that contribute to this variability, including acquisition technique, software variability, and observer variability and intrinsic factors such as tumor heterogeneity. However, on a practical level, identical scanning acquisition parameters and techniques were used in each of the paired studies, and analysis was performed by a single observer using the same software package, minimizing variability from these factors. It is a reasonable assumption that compensation for intrinsic spatial heterogeneity is a major factor contributing to this improvement.

In summary, we have shown that measurement reproducibility improves with increasing tumor coverage. Assessing perfusion over a greater tumor volume may provide more reliable assessment and should be considered in clinical practice. This technique can potentially be used to evaluate whole-tumor vascularity, and further work in developing this technique is ongoing.


References
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 

  1. Tozer GM. Measuring tumor vascular response to antivascular and antiangiogenic drugs. Br J Radiol 2003;76 : S23-S35[Abstract/Free Full Text]
  2. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979: WHO offset publication no. 48
  3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205 -216[Abstract/Free Full Text]
  4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2000;2 : 727-739
  5. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10 : 145-147[CrossRef][Medline]
  6. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol2003; 21:2823 -2830[Abstract/Free Full Text]
  7. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol2003; 21:2831 -2842[Abstract/Free Full Text]
  8. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21 : 4428-4438[Abstract/Free Full Text]
  9. Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumor. Phys Med Biol 2001; 46:3161 -3175[CrossRef][Medline]
  10. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. Dynamic CT measurement of cerebral blood flow: a validation study. AJNR 1999; 20:63 -73[Abstract/Free Full Text]
  11. Gobbel GT, Cann CE, Iwamoto HS, Fike JR. Measurement of regional cerebral blood flow in the dog using ultrafast computed tomography: experimental validation. Stroke 1991;22 : 772-779[Abstract/Free Full Text]
  12. Gobbel GT, Cann CE, Fike JR. Comparison of xenon-enhanced CT with ultrafast CT for measurement of regional cerebral blood flow. AJNR 1993; 14:543 -550[Abstract]
  13. Wintermark M, Thiran JP, Maeder P, Schnyder P, Meuli R. Simultaneous measurement of regional cerebral blood flow by perfusion CT and stable xenon CT: a validation study. AJNR2001; 22:905 -914[Abstract/Free Full Text]
  14. Gillard JH, Minhas PS, Hayball MP, et al. Assessment of quantitative computed tomographic cerebral perfusion imaging with H2(15)O positron emission tomography. Neurol Res 2000; 22:457 -464[Medline]
  15. Jinzaki M, Tanimoto A, Mukai M, et al. Double phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr2000; 24:835 -842[CrossRef][Medline]
  16. Yi CA, Lee KS, Kim EA, et al. Solitary pulmonary nodules: dynamic enhanced multidetector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology2004; 233:191 -199[Abstract/Free Full Text]
  17. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 2002;26 : 185-190[CrossRef][Medline]
  18. Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumors. Br J Cancer 1995; 71:1210 -1213[Medline]
  19. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996;56 : 5522-5528[Abstract/Free Full Text]
  20. Patlak CS, Balsberg RG, Fernstmacher JD. Graphical evaluation of blood to brain transfer constants from multiple time uptake data. J Cereb Blood Flow Metab 1983;3 : 1-7[Medline]
  21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet1986; 1:307 -310[CrossRef][Medline]
  22. Bland JM, Altman DG. Statistics notes: measurement error. BMJ 1996; 312:1654 , corrected and republished in BMJ 1996; 313:1654[Free Full Text]
  23. Bland JM, Altman DG. Statistics notes: measurement error proportional to the mean. BMJ 1996;313 : 106[Free Full Text]
  24. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8 : 135-160[Abstract/Free Full Text]
  25. Bland JM, Altman DG. Applying the right statistics: analysis of measurement studies. Ultrasound Obstet Gynecol2003; 22:85 -93[Medline]
  26. Miles KA, Griffiths MR, Fuentes MA. Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG-PET in lung nodules. Radiology 2001;220 : 548-553[Abstract/Free Full Text]
  27. Nabavi DG, Cenic A, Dool J, et al. Quantitative assessment of cerebral hemodynamics using CT: stability, accuracy, and precision studies in dogs. J Comput Assist Tomogr 1999;23 : 506-515[CrossRef][Medline]
  28. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. AJNR 2000;21 : 462-470[Abstract/Free Full Text]
  29. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumors: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002; 15:132 -142[CrossRef][Medline]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
V. Goh, J. Liaw, C. I. Bartram, and S. Halligan
Effect of Temporal Interval Between Scan Acquisitions on Quantitative Vascular Parameters in Colorectal Cancer: Implications for Helical Volumetric Perfusion CT Techniques
Am. J. Roentgenol., December 1, 2008; 191(6): W288 - W292.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ng, Q. S.
Right arrow Articles by Padhani, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, Q. S.
Right arrow Articles by Padhani, A. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS